Related references
Note: Only part of the references are listed.KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
Jin Hyun Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer
Cecily P. Vaughn et al.
GENES CHROMOSOMES & CANCER (2011)
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
Timothy J. Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
D. Santini et al.
ANNALS OF ONCOLOGY (2010)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
Surgery for colorectal liver metastases
J. N. Primrose
BRITISH JOURNAL OF CANCER (2010)
Surgical management and outcomes of colorectal cancer liver metastases
E. J. A. Morris et al.
BRITISH JOURNAL OF SURGERY (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Gunnar Folprecht et al.
LANCET ONCOLOGY (2010)
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
Jeffrey W. Tyner et al.
BLOOD (2009)
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
Youji He et al.
CLINICAL CANCER RESEARCH (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Amy J. French et al.
CLINICAL CANCER RESEARCH (2008)
Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics
Guoren Deng et al.
EUROPEAN JOURNAL OF CANCER (2008)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
RAS signaling in colorectal carcinomas through alterations of RAS, RAF, NF1, and/or RASSF1A
Terje Ahlquist et al.
NEOPLASIA (2008)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Survival after hepatic resection in metastatic colorectal cancer - A population-based study
Linda C. Cummings et al.
CANCER (2007)
Germline KRAS mutations cause Noonan syndrome
S Schubbert et al.
NATURE GENETICS (2006)
Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations
IJ Kim et al.
CARCINOGENESIS (2006)
Extending the frontiers of surgical therapy for hepatic colorectal metastases: Is there a limit?
VP Khatri et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Prognostic scoring in colorectal cancer liver metastases - Development and validation
M Schindl et al.
ARCHIVES OF SURGERY (2005)
Different genetic features associated with colon and rectal carcinogenesis
M Frattini et al.
CLINICAL CANCER RESEARCH (2004)
Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer
JM Ferraz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Share Paper
